Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

581
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
581
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

840
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
840
Assessment of the Gastrointestinal System II: Health Perception Pattern01:29

Assessment of the Gastrointestinal System II: Health Perception Pattern

446
Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health Perception Patterns
Health perception patterns offer valuable insights into a patient's lifestyle habits and how they may impact their GI health. These patterns include:
446
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

595
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
595
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

582
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
582
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

2.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
2.2K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Indian society of electrocardiology position statement on improving CPR awareness in the Indian public.

Indian heart journal·2026
Same author

Use of technology and AI tools in type 2 diabetes.

Best practice & research. Clinical endocrinology & metabolism·2026
Same author

Real-world evidence of urinary tract infections and genital tract infections with sodium-glucose cotransporter-2 inhibitors (SGLT2i) alone or in combination with dipeptidyl peptidase-4 inhibitors (DPP4i) in individuals with type-2 diabetes mellitus in India.

BMC endocrine disorders·2026
Same author

Obstructive sleep apnea: Proposed scoring system.

World journal of methodology·2026
Same author

Integrated Management of Cardio-Renal-Metabolic Disorders in India: A Nationwide Physician Survey.

Cureus·2026
Same author

A multicentre survey of liver fibrosis burden in type 2 diabetes in India: the DiaFib-Liver Study.

The Lancet regional health. Southeast Asia·2026

相关实验视频

Updated: Jan 15, 2026

A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli
08:01

A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli

Published on: August 12, 2016

9.4K

恩帕格利弗洛辛的感知映射调查调查

Rajiv Kovil1, Vijay Panikar2, Jothydev Kesavadev3

  • 1Diabetes and Endocrinology, Zandra Healthcare, Mumbai, IND.

Cureus
|January 14, 2026
PubMed
概括
此摘要是机器生成的。

印度医生承认empagliflozin.

关键词:
慢性脏疾病 慢性脏疾病艾姆帕格利夫洛辛 (Empagliflozin) 是一种心脏衰竭是因为心脏衰竭.医生看法 医生看法这是一种sglt2抑制剂.2型糖尿病是什么?

更多相关视频

Behavioral Assessment of Visual Function via Optomotor Response and Cognitive Function via Y-Maze in Diabetic Rats
07:41

Behavioral Assessment of Visual Function via Optomotor Response and Cognitive Function via Y-Maze in Diabetic Rats

Published on: October 23, 2020

6.7K
Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

10.8K

相关实验视频

Last Updated: Jan 15, 2026

A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli
08:01

A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli

Published on: August 12, 2016

9.4K
Behavioral Assessment of Visual Function via Optomotor Response and Cognitive Function via Y-Maze in Diabetic Rats
07:41

Behavioral Assessment of Visual Function via Optomotor Response and Cognitive Function via Y-Maze in Diabetic Rats

Published on: October 23, 2020

6.7K
Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

10.8K

科学领域:

  • 心脏病学 心脏病学
  • 内分泌学 在内分泌学.
  • 腎臟病學 (nephrology) 是一種醫學.

背景情况:

  • 心力衰竭 (HF) 是一种常见的,往往未被发现的,伴随着2型糖尿病 (T2DM) 的并发症.
  • 恩帕格利弗洛辛是一种-葡萄糖共运输体-2 (SGLT2) 抑制剂,具有已证明的心血管和功能益处,得到国际指南的支持.
  • 阻碍对empagliflozin采用的障碍包括诊断挑战,成本和临床医生的熟悉性.

研究的目的:

  • 评估印度医生对T2DM患者对empagliflozin的看法和处方做法.
  • 确定人们对empagliflozin的益处和在各种T2DM个人资料中使用它的障碍的认识.

主要方法:

  • 一个横截面的,基于问卷的医生管理T2DM的调查.
  • 收集了有关人口统计,高频风险评估,SGLT2抑制剂处方,感知到的益处和障碍的数据.
  • 匿名医生回复的描述性分析.

主要成果:

  • 医生承认T2DM中HF的诊断不足,并承认empagliflozin在心脏关联疾病中的作用.
  • 在T2DM中报告的频繁使用empagliflozin与心血管风险因素,动脉样硬化心血管疾病 (ASCVD) 和慢性病 (CKD).
  • 处方趋势反映了empagliflozin在心力衰竭中具有降低 (HFrEF) 和保留射出分数 (HFpEF) 的好处.
  • 成本,指南意识和治疗惯性被确定为障碍.

结论:

  • 印度医生表现出强烈的意识和指导方针对T2DM与心并发症的empagliflozin的处方.
  • 无症状HF的低认可和CKD管理的变化需要有针对性的教育和政策举措.
  • 加强基于证据的实践需要解决这些已识别的差距.